IP Library Granted Patent US 10,709,691
Granted Patent B2
US 10,709,691 · App. 16/175,082 · Granted Jul 14, 2020

Pharmaceutical dosage forms

Inventors: Stefania Beato (Basel, CH); Peggy Quinton (Waldighoffen, FR)
Assignee: RECORDATI AG
A61K31/4188A61K9/2009A61K9/2036A61K9/2054A61K9/2095A61K9/2813A61K9/2826A61K9/2866A61K31/4184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,691
App. No.
16/175,082
Granted
Jul 14, 2020
Kind
B2
Abstract

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

Claims (6)

1. A method of treating Cushing's disease or Cushing's syndrome with a pharmaceutical dosage form for oral administration comprising: (a) a drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]3-fluorobenzonitrile as defined by formula (1)

or any pharmaceutically acceptable salt thereof, and (b) 70% to 95% by weight of microcrystalline cellulose based on the total weight of said pharmaceutical dosage form.

2. The method according to claim 1 , wherein the drug substance is present as phosphate salt.

3. The method according to claim 2 , wherein the drug substance is present as a mono-phosphate sa it.

4. The method according to claim 1 , wherein the drug substance, calculated based on its free base, is present from 0.5 to 20% by weight based on the total weight of said pharmaceutical dosage form.

5. The method according to claim 1 , wherein 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof is combined with 70% to 95% by weight of microcrystalline cellulose based on the total weight of said pharmaceutical dosage form into a pharmaceutically processable material to provide the pharmaceutical dosage form for oral administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: NOVARTIS AG
To: RECORDATI AG
Reel/Frame 051945/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: BEATO, STEFANIA; QUINTON, PEGGY
To: NOVARTIS PHARMA AG
Reel/Frame 051818/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 051818/0311 →
Continuity (3)
Continuation 15323991
Provisional Application 62021271 · Jul 7, 2014
Related Publication 20190060283A1 · Feb 28, 2019